ZM323881 HCl
new
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 405610

CAS#: 193000-39-4 (HCl)

Description: ZM323881 is a potent and selective inhibitor of VEGF-R2 tyrosine kinase in vitro (IC(50) < 2 nM), compared with other receptor tyrosine kinases, including VEGF-R1 (IC(50) > 50 microM). ZM323881 inhibits VEGF-A-induced endothelial cell proliferation (IC(50) = 8 nM) and VEGF-R2 tyrosine phosphorylation in vitro.

Chemical Structure

img
ZM323881 HCl
CAS# 193000-39-4 (HCl)
Instruction

Theoretical Analysis

MedKoo Cat#: 405610
Name: ZM323881 HCl
CAS#: 193000-39-4 (HCl)
Chemical Formula: C22H19ClFN3O2
Exact Mass: 375.14
Molecular Weight: 411.115
Elemental Analysis: C, 64.16; H, 4.65; Cl, 8.61; F, 4.61; N, 10.20; O, 7.77

Price and Availability

Size Price Availability Quantity
5mg USD 325 2 Weeks
25mg USD 750 2 Weeks
50mg USD 1050 2 Weeks
100mg USD 1650 2 Weeks
Bulk inquiry

Related CAS #: 324077-30-7 (free base)   193000-39-4 (HCl)    

Synonym: ZM323881; ZM 323881; ZM-323881; ZM323881 HCl; ZM323881 hydrochloride

IUPAC/Chemical Name: 5-((7-Benzyloxyquinazolin-4-yl)amino)-4-fluoro-2-methylphenol hydrochloride

InChi Key: AVRHWGLIYGJSOD-UHFFFAOYSA-N

InChi Code: InChI=1S/C22H18FN3O2.ClH/c1-14-9-18(23)20(11-21(14)27)26-22-17-8-7-16(10-19(17)24-13-25-22)28-12-15-5-3-2-4-6-15;/h2-11,13,27H,12H2,1H3,(H,24,25,26);1H

SMILES Code: OC1=CC(NC2=C3C=CC(OCC4=CC=CC=C4)=CC3=NC=N2)=C(F)C=C1C.[H]Cl

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years

Solubility: Soluble in DMSO, not in water

Shelf Life: >5 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:   Related CAS# 324077-30-7 ( ZM323881 free base) 193000-39-4 ( ZM323881 HCl).      

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 411.12 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Gyurkovics M, Lohinai Z, Győrfi A, Bodor C, Székely AD, Dinya E, Rosivall L. Microvascular regulatory role and increased expression of vascular endothelial growth factor receptor type 2 in experimental gingivitis. J Periodontal Res. 2012 Sep 7. doi: 10.1111/j.1600-0765.2012.01520.x. [Epub ahead of print] PubMed PMID: 22957787.

2: Urschel K, Garlichs CD, Daniel WG, Cicha I. VEGFR2 signalling contributes to increased endothelial susceptibility to TNF-α under chronic non-uniform shear stress. Atherosclerosis. 2011 Dec;219(2):499-509. doi: 10.1016/j.atherosclerosis.2011.09.045. Epub 2011 Oct 4. PubMed PMID: 22019447.

3: Bills VL, Salmon AH, Harper SJ, Overton TG, Neal CR, Jeffery B, Soothill PW, Bates DO. Impaired vascular permeability regulation caused by the VEGF₁₆₅b splice variant in pre-eclampsia. BJOG. 2011 Sep;118(10):1253-61. doi: 10.1111/j.1471-0528.2011.02925.x. Epub 2011 Jun 14. PubMed PMID: 21668772.

4: Uniewicz KA, Cross MJ, Fernig DG. Exogenous recombinant dimeric neuropilin-1 is sufficient to drive angiogenesis. J Biol Chem. 2011 Jan 7;286(1):12-23. doi: 10.1074/jbc.M110.190801. Epub 2010 Oct 18. PubMed PMID: 20956519; PubMed Central PMCID: PMC3012965.

5: Gyurkovics M, Lohinai Z, Gyorfi A, Iványi I, Süveges I, Kónya M, Bodor C, Székely AD, Dinya E, Fazekas A, Rosivall L. Venodilatory effect of vascular endothelial growth factor on rat gingiva. J Periodontol. 2009 Sep;80(9):1518-23. doi: 10.1902/jop.2009.080651. PubMed PMID: 19722804.

6: Cao R, Jensen LD, Söll I, Hauptmann G, Cao Y. Hypoxia-induced retinal angiogenesis in zebrafish as a model to study retinopathy. PLoS One. 2008 Jul 23;3(7):e2748. doi: 10.1371/journal.pone.0002748. PubMed PMID: 18648503; PubMed Central PMCID: PMC2447178.

7: Ablonczy Z, Crosson CE. VEGF modulation of retinal pigment epithelium resistance. Exp Eye Res. 2007 Dec;85(6):762-71. Epub 2007 Aug 24. PubMed PMID: 17915218; PubMed Central PMCID: PMC2199266.

8: Xiao Z, Kong Y, Yang S, Li M, Wen J, Li L. Upregulation of Flk-1 by bFGF via the ERK pathway is essential for VEGF-mediated promotion of neural stem cell proliferation. Cell Res. 2007 Jan;17(1):73-9. Epub 2007 Jan 9. PubMed PMID: 17211450.

9: Kim DS, Franklyn JA, Boelaert K, Eggo MC, Watkinson JC, McCabe CJ. Pituitary tumor transforming gene (PTTG) stimulates thyroid cell proliferation via a vascular endothelial growth factor/kinase insert domain receptor/inhibitor of DNA binding-3 autocrine pathway. J Clin Endocrinol Metab. 2006 Nov;91(11):4603-11. Epub 2006 Aug 22. PubMed PMID: 16926250.

10: Glass CA, Harper SJ, Bates DO. The anti-angiogenic VEGF isoform VEGF165b transiently increases hydraulic conductivity, probably through VEGF receptor 1 in vivo. J Physiol. 2006 Apr 1;572(Pt 1):243-57. Epub 2006 Jan 19. PubMed PMID: 16423853; PubMed Central PMCID: PMC1779637.